Literature DB >> 6975635

Therapeutic plasmapheresis in systemic lupus erythematosus. Effect on immune complexes and antibodies to DNA.

J V Jones, M F Robinson, R K Parciany, L F Layfer, B McLeod.   

Abstract

The effect of plasmapheresis in 8 patients with systemic lupus erythematosus (SLE) was investigated. Drug treatment was maintained at a constant level for at least 4 weeks before plasmapheresis. Levels of immune complexes were measured by a Raji cell radioimmunoassay, and by a solid-phase C1q-binding assay. Antibodies to ds-DNA and ss-DNA were measured by the Farr assay. In all cases, immune complexes and antibodies were lowered by plasmapheresis. In 5 patients, plasmapheresis was followed by a rapid rebound of complexes and antibody to pretreatment levels. In 3 in whom plasmapheresis was followed by treatment with cyclophosphamide for 1 month, a sustained immunochemical and clinical improvement followed, lasting in 2 cases for up to 3 years.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6975635     DOI: 10.1002/art.1780240901

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  14 in total

1.  Effect of plasmapheresis on ligand binding capacity and expression of erythrocyte complement receptor type 1 (CR1) of patients with systemic lupus erythematosus (SLE).

Authors:  I Csípö; E Kiss; P Soltész; P Antal-Szalmás; G Szegedi; J H Cohen; R P Taylor; M Kávai
Journal:  Clin Exp Immunol       Date:  1999-12       Impact factor: 4.330

2.  Internal medicine-important advances in clinical medicine: plasmapheresis as therapy.

Authors:  R T Reid; A M Jaffer
Journal:  West J Med       Date:  1983-05

3.  Pilot clinical study of Adacolumn cytapheresis in patients with systemic lupus erythematosus.

Authors:  Helmut Soerensen; Jana-Maria Schneidewind-Mueller; Doris Lange; Nobuhito Kashiwagi; Marita Franz; Takashi Yokoyama; Wolfgang Ramlow
Journal:  Rheumatol Int       Date:  2005-09-28       Impact factor: 2.631

4.  New approaches to treating systemic lupus erythematosus.

Authors:  D Wofsy
Journal:  West J Med       Date:  1987-08

5.  Rebound of anti-topoisomerase I antibody titres after plasma exchange.

Authors:  F H Van den Hoogen; A M Boerbooms; L B Van de Putte; R Verheijen; W Van Venrooij; A J Croockewit
Journal:  Ann Rheum Dis       Date:  1993-03       Impact factor: 19.103

6.  The clinical effect and the effect on serum IgG antibodies to peripheral nerve tissue of plasma exchange in patients wit Guillain-Barré syndrome.

Authors:  C A Vedeler; H Nyland; J Fagius; P O Osterman; R Matre; J A Aarli; R W Janzen; H Jacobsen; H Skre
Journal:  J Neurol       Date:  1982       Impact factor: 4.849

7.  Where now for therapeutic apheresis?

Authors:  T Hamblin
Journal:  Br Med J (Clin Res Ed)       Date:  1984-09-29

8.  Plasmapheresis in clinical medicine.

Authors:  C Linker
Journal:  West J Med       Date:  1983-01

9.  Selective removal of anti-double-stranded DNA antibodies by immunoadsorption with dextran sulphate in a patient with systemic lupus erythematosus.

Authors:  M Kinoshita; S Aotsuka; T Funahashi; N Tani; R Yokohari
Journal:  Ann Rheum Dis       Date:  1989-10       Impact factor: 19.103

Review 10.  The treatment of lupus nephritis.

Authors:  J S Cameron
Journal:  Pediatr Nephrol       Date:  1989-07       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.